Condition
Malignant Neoplasms of Thyroid and Other Endocrine Glands
Total Trials
4
Recruiting
1
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 1 (4)
Trial Status
Active Not Recruiting2
Withdrawn1
Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT03435952Phase 1Active Not Recruiting
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
NCT03162627Phase 1Active Not Recruiting
Selumetinib and Olaparib in Solid Tumors
NCT03093909Phase 1Recruiting
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
NCT02915172Phase 1Withdrawn
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
Showing all 4 trials